Maryan Lelyukh, Myroslava Kalytovska, Marta Zastryzhna, Arkadii Savchenko, Ihor Chaban, Stefan Harkov
{"title":"Synthesis and antitumor activity of 1,3,4-oxadiazole substituted 2-(5-ylidene-2,4-dioxothiazolidin-3-yl)-acetamides","authors":"Maryan Lelyukh, Myroslava Kalytovska, Marta Zastryzhna, Arkadii Savchenko, Ihor Chaban, Stefan Harkov","doi":"10.3897/pharmacia.70.e102449","DOIUrl":null,"url":null,"abstract":"A series of novel 1,3,4-oxadiazole substituted 2-(5-aryl/heterylidene-2,4-dioxothiazolidine-3-ylidene)-acetamides and their 5-unsubstituted analogues have been synthesized following N -alkylation reaction of 2-chloro- N -(5-aryl-[1,3,4]oxadiazol-2-yl)-acetamides with thiazolidinedione and potassium salts of its arylidene derivatives. The structures of target compounds were confirmed by using 1H NMR spectroscopy and elemental analysis. Evaluation of anticancer activity in vitro for the synthesized compounds was performed in accordance with the National Cancer Institute protocol. A selective influence of some tested compounds against leukaemia MOLT-4 ( 3e , GP = 76.85%) and K-562 ( 3e , GP = 79.84%), colon cancer HCT-15 ( 3d , GP = 76.86%), renal cancer A498 ( 4a , GP = 74.37%), CAKI-1 ( 3d , GP = 68.49%) and UO-31 ( 3b-e, 4a-b , GP = 66.67 ÷ 86.30%) cell lines was established. Grafical abstract :","PeriodicalId":20086,"journal":{"name":"Pharmacia","volume":"16 1","pages":"0"},"PeriodicalIF":1.1000,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3897/pharmacia.70.e102449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
A series of novel 1,3,4-oxadiazole substituted 2-(5-aryl/heterylidene-2,4-dioxothiazolidine-3-ylidene)-acetamides and their 5-unsubstituted analogues have been synthesized following N -alkylation reaction of 2-chloro- N -(5-aryl-[1,3,4]oxadiazol-2-yl)-acetamides with thiazolidinedione and potassium salts of its arylidene derivatives. The structures of target compounds were confirmed by using 1H NMR spectroscopy and elemental analysis. Evaluation of anticancer activity in vitro for the synthesized compounds was performed in accordance with the National Cancer Institute protocol. A selective influence of some tested compounds against leukaemia MOLT-4 ( 3e , GP = 76.85%) and K-562 ( 3e , GP = 79.84%), colon cancer HCT-15 ( 3d , GP = 76.86%), renal cancer A498 ( 4a , GP = 74.37%), CAKI-1 ( 3d , GP = 68.49%) and UO-31 ( 3b-e, 4a-b , GP = 66.67 ÷ 86.30%) cell lines was established. Grafical abstract :
以2-氯- N -(5-芳基-[1,3,4]恶二唑-2-基)-乙酰酰胺为原料，与噻唑烷二酮及其芳基衍生物的钾盐进行N -烷基化反应，合成了一系列新的1,3,4-恶二唑取代的2-(5-芳基/杂基-2,4-二氧噻唑-3-芳基)-乙酰酰胺及其5-未取代的类似物。目的化合物的结构经核磁共振氢谱和元素分析证实。合成化合物的体外抗癌活性评估按照美国国家癌症研究所的方案进行。部分化合物对白血病MOLT-4 (3e, GP = 76.85%)和K-562 (3e, GP = 79.84%)、结肠癌HCT-15 (3d, GP = 76.86%)、肾癌A498 (4a, GP = 74.37%)、CAKI-1 (3d, GP = 68.49%)和UO-31 (3b-e, 4a-b, GP = 66.67 ÷ 86.30%)细胞株有选择性影响。图形摘要:
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
